How a desert lizard's venom became the best-selling medicines on Earth. We trace the science of GLP-1 receptor agonists from 1990 — when endocrinologist John Eng isolated exendin-4 from Gila monster venom, a hormone that mimics human GLP-1 but lasts hours instead of two minutes — through the drug lineage it spawned: exenatide (Byetta), liraglutide, semaglutide (Ozempic/Wegovy), the dual GIP/GLP-1 agonist tirzepatide (Mounjaro/Zepbound), and the triple agonist retatrutide. Hosts Hope and Lauren unpack the incretin biology and the decades-long "half-life arms race," how each generation pushed diabetes control and weight loss further, and the delightful surprises now emerging in the clinic — cardiovascular protection (SELECT), chronic kidney disease, obstructive sleep apnea, fatty-liver disease, and early signals in cravings and the aging brain — alongside the very real GI side effects that come with them.
This episode was generated by AI from the cited research paper.